| International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma SV Rajkumar, MA Dimopoulos, A Palumbo, J Blade, G Merlini, MV Mateos, ... The lancet oncology 15 (12), e538-e548, 2014 | 4947 | 2014 |
| International uniform response criteria for multiple myeloma BGM Durie, JL Harousseau, JS Miguel, J Blade, B Barlogie, K Anderson, ... Leukemia 20 (9), 1467-1473, 2006 | 3439 | 2006 |
| Molecular mechanisms of amyloidosis G Merlini, V Bellotti New England Journal of Medicine 349 (6), 583-596, 2003 | 2400 | 2003 |
| Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy MS Maurer, JH Schwartz, B Gundapaneni, PM Elliott, G Merlini, ... New England Journal of Medicine 379 (11), 1007-1016, 2018 | 1939 | 2018 |
| Nonbiopsy diagnosis of cardiac transthyretin amyloidosis JD Gillmore, MS Maurer, RH Falk, G Merlini, T Damy, A Dispenzieri, ... Circulation 133 (24), 2404-2412, 2016 | 1663 | 2016 |
| Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International … MA Gertz, R Comenzo, RH Falk, JP Fermand, BP Hazenberg, ... American journal of hematology 79 (4), 319-328, 2005 | 1527 | 2005 |
| Inotersen treatment for patients with hereditary transthyretin amyloidosis MD Benson, M Waddington-Cruz, JL Berk, M Polydefkis, PJ Dyck, ... New England Journal of Medicine 379 (1), 22-31, 2018 | 1212 | 2018 |
| International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders A Dispenzieri, R Kyle, G Merlini, JS Miguel, H Ludwig, R Hájek, ... Leukemia 23 (2), 215-224, 2009 | 1049 | 2009 |
| Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and … RA Kyle, BGM Durie, SV Rajkumar, O Landgren, J Bladé, G Merlini, ... Leukemia 24 (6), 1121-1127, 2010 | 1013 | 2010 |
| Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study SK Kumar, JH Lee, JJ Lahuerta, G Morgan, PG Richardson, J Crowley, ... Leukemia 26 (1), 149-157, 2012 | 1006 | 2012 |
| New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes G Palladini, A Dispenzieri, MA Gertz, S Kumar, A Wechalekar, ... J Clin Oncol 30 (36), 4541-4549, 2012 | 920 | 2012 |
| Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types C Rapezzi, G Merlini, CC Quarta, L Riva, S Longhi, O Leone, F Salvi, ... Circulation 120 (13), 1203-1212, 2009 | 844 | 2009 |
| Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial JL Berk, OB Suhr, L Obici, Y Sekijima, SR Zeldenrust, T Yamashita, ... Jama 310 (24), 2658-2667, 2013 | 718 | 2013 |
| Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines JD Sipe, MD Benson, JN Buxbaum, S Ikeda, G Merlini, MJM Saraiva, ... Amyloid 23 (4), 209-213, 2016 | 694 | 2016 |
| Amyloidosis: pathogenesis and new therapeutic options G Merlini, DC Seldin, MA Gertz Journal of Clinical Oncology 29 (14), 1924, 2011 | 632 | 2011 |
| Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis JD Sipe, MD Benson, JN Buxbaum, S Ikeda, G Merlini, MJM Saraiva, ... Amyloid 21 (4), 221-224, 2014 | 630 | 2014 |
| Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases P Garcia-Pavia, C Rapezzi, Y Adler, M Arad, C Basso, A Brucato, ... European heart journal 42 (16), 1554-1568, 2021 | 609 | 2021 |
| ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2—evidence base and standardized methods of … S Dorbala, Y Ando, S Bokhari, A Dispenzieri, RH Falk, VA Ferrari, ... Journal of Nuclear Cardiology 26, 2065-2123, 2019 | 609* | 2019 |
| Serum N-terminal pro–brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis G Palladini, C Campana, C Klersy, A Balduini, G Vadacca, V Perfetti, ... Circulation 107 (19), 2440-2445, 2003 | 596 | 2003 |
| Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee MD Benson, JN Buxbaum, DS Eisenberg, G Merlini, MJM Saraiva, ... Amyloid 25 (4), 215-219, 2018 | 579 | 2018 |
